Phase III study (MONET1) of motesanib plus carboplatin/ paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 529-536

  Kubota, K ^a   Ichinose, Y ^b   Scagliotti, G ^c   Spigel, D ^d   Kim, J H ^e   Shinkai, T ^f   Takeda, K ^g   Kim, S W ^h   Hsia, T C ^i,j   Li, R K ^k   Tiangco, B J ^l   Yau, S ^m   Lim, W T ⁿ   Yao, B ^o   Hei, Y J ^o   Park, K ^p  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c UNIVERSITY OF TURIN   (Italy)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e Yonsei University College of Medicine   (South Korea)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h University of Ulsan College of Medicine   (South Korea)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

^j CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^k ST LUKE S MEDICAL CENTER   (Philippines)

^l National Kidney and Transplant Institute Philippines   (Philippines)

^m QUEEN ELIZABETH HOSPITAL   (Hong Kong)

ⁿ DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^o AMGEN INC   (United States)

^p Sungkyunkwan University School of Medicine   (South Korea)

more..

Author keywords

Asia; Carboplatin; Motesanib; NSCLC; Paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; MOTESANIB; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; IMETELSTAT; INDOLE DERIVATIVE; NICOTINAMIDE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASIAN; ASTHENIA; BACKACHE; CANCER RECURRENCE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HICCUP; HUMAN; HYPERTENSION; INSOMNIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; OROPHARYNX PAIN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SENSORY NEUROPATHY; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893352389     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt552     Document Type: Article

References (28)

1. Wu YL, Park K, Soo RA et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011; 11: 430.
2. GLOBOCAN 2008. Cancer Incidence, Mortality and Prevalence Worldwide in 2008. http://globocan.iarc.fr/. 2008 (25 October 2013, date last accessed).
3. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010; 67: 257-74.
4. Freedman ND, Leitzmann MF, Hollenbeck AR et al. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 2008; 9: 649-56.
5. Huxley R, Jamrozik K, Lam TH et al. Impact of smoking and smoking cessation on lung cancer mortality in the Asia-Pacific region. Am J Epidemiol 2007; 165: 1280-6.
6. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
7. Scagliotti GV, Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist 2010; 15: 436-46.
8. Polverino A, Coxon A, Starnes C et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66: 8715-21.
9. Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 2369-76.
10. Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-42.
11. Blumenschein GR, Jr, Kabbinavar F, Menon H et al. A phase II, multicenter, openlabel randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011; 22: 2057-67.
12. Scagliotti GV, Vynnychenko I, Park K et al. International, randomized, placebocontrolled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012; 30: 2829-36.
13. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009; 4: 1083-93.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
15. Saijo N, Fukuoka M, Thongprasert S et al. Lung cancer working group report. Jpn J Clin Oncol 2010; 40 (Suppl 1): i7-12.
16. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-20.
17. Ciardiello F, Troiani T, Bianco R et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006; 17 (Suppl 7): vii109-14.
18. Mok TS, Hsia TC, Tsai CM et al. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous nonsmall cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol 2011; 7 (Suppl 2): 4-12.
19. Scagliotti GV, Krzakowski M, Szczesna A et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012; 30: 2070-8.
20. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009; 27: 3540-6.
21. Blumenschein GR, Jr, Reckamp K, Stephenson GJ et al. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/ paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 279-90.
22. Kawaguchi T, Matsumura A, Fukai S et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010; 5: 1001-10.
23. Ahn MJ, Lee J, Park YH et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol 2010; 5: 1185-96.
24. Kim JH, Kim SY, Jung KH et al. Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. Lung Cancer 2006; 52: 75-81.
25. Park JO, Kim SW, Ahn JS et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25: 5233-9.
26. Okamoto I, Yoshioka H, Takeda K et al. Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. J Thorac Oncol 2012; 7: 427-33.
27. Tsai CM, Au JS, Chang GC et al. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study. J Thorac Oncol 2011; 6: 1092-7.
28. Zhao X, Mei K, Cai X et al. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Invest New Drugs 2012; 30: 1144-9.